Home » Business News » 2013 » July » July 1, 2013

Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (30 June 2013)

July 1, 2013 - Bagsvaerd, Denmark

In continuation of the company'sannouncements dated 31 January 2013 and 3 May 2013 concerning planned sharerepurchase programmes, and pursuant to Section 204.25 of the New York StockExchange Listed Company Manual, this is to report that Novo Nordisk A/S(NYSE: NVO) and its wholly-owned affiliates on 30 June 2013 owned14,976,660 of its own B shares of DKK 1, corresponding to a total nominalvalue of DKK 14,976,660 or 2.7% of the total share capital.

In the second quarter of 2013 a total of 5,400,500 B shares wererepurchased, and 82,169 B shares were disposed of to employees inconnection with employee incentive programmes.

Novo Nordisk is a global healthcare company with 90 years of innovation andleadership in diabetes care. The company also has leading positions withinhaemophilia care, growth hormone therapy and hormone replacement therapy.Headquartered in Denmark, Novo Nordisk employs approximately 35,000employees in 75 countries, and markets its products in more than 180countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Formore information, visit

Company Announcement No 48 / 2013:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Further information
Anne Margrethe Hauge
+45 4442 3450
Email Contact

Ken Inchausti (US)
+1 609 514 8316
Email Contact

Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact

Frank Daniel Mersebach
+45 4442 0604
Email Contact

Lars Borup Jacobsen
+45 3075 3479
Email Contact

Jannick Lindegaard (US)
+1 609 786 4575
Email Contact


Comment on this story